CTRI/2017/07/009103
Recruiting
Phase 4
â??Clinical evaluation of efficacy and safety of 3 µg/kg Fentanyl to prevent haemodynamic stress response during laryngoscopy and intubarion in normotensive v/s hypertensive population: A prospective, double blind clinical study.â??
Department of Anaesthesiology Sir T Hospital Bhavnagar0 sites100 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- patient under going surgery which requires general anasthesia
- Sponsor
- Department of Anaesthesiology Sir T Hospital Bhavnagar
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •NORMOTENSIVE PATIENT:
- •1Age:20 to 50 years
- •2Gender: Male and Female
- •3ASA physical status I and II
- •4Patient posted for elective surgery under general anaesthesia requiring endotracheal intubation
- •5Surgery duration less than two hours
- •6BMI \<\= 25kg/m2\.
- •7Informed written consent for participation in study.
- •8Modified Mallampatti Classification I and II
- •HYPERTENSIVE PATIENT:
Exclusion Criteria
- •1Patient refusing consent
- •2Patient with Diabetes ,COPD, Renal disease, Cardiac diseases like IHD, Valvular heart disease, AV conduction block, LVF \& Psychiatric illness etc.
- •3Patient on drugs likes sedatives, opioids, anti\-psychiatrics and β blockers.
- •4ASA physical status III and above.
- •5Anticipated difficult intubation.
- •6BMI 25\>\=kg/m2
- •7Intubation attempt lasting more than 20seconds
- •8Patient on more than 3 antihypertensive medications.
- •9Defaulter of taking antihypertensive medication as per schedule
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2016-000685-39-FRovo Nordisk A/S372
Active, not recruiting
Phase 1
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2016-000685-39-NLovo Nordisk A/S288
Active, not recruiting
Phase 1
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2016-000685-39-FIovo Nordisk A/S372
Active, not recruiting
Phase 1
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2016-000685-39-DKovo Nordisk A/S288
Completed
Phase 2
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis10019654NL-OMON47918ovo Nordisk12